FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3142122489> ?p ?o ?g. }

• W3142122489 endingPage "S768" @default.
• W3142122489 startingPage "S767" @default.
• W3142122489 abstract "Background: Non-small cell lung cancer is one cancer which has seen radical change in treatment in the last decade with the advent of immunotherapy and targeted therapies. Chemo immunotherapy has increased the survival multi fold in metastatic setting and also in earlier lines and is the first line treatment now in non driver mutation setting. However, applicability of the same into real world practice has been dismal in low and middle income countries due to various reasons. Data is lacking in this setting. Methods: We conducted a prospective observational study to see the applicability of Immuno Oncology drug indications in stage 3 and 4 NSCLC patients. Consecutive patients between March 2018 and February 2020 who had an approved indication for IO regimen usage were included. Stage 3b and 3c and stage 4 driver mutation negative patients were taken into the study. Their treatment regimens were studied and reasons for non usage of IO regimen were assessed. Results: Between March 2018 and February 2020, 88 patients were enrolled who were eligible for treatment with IO agents in NSCLC. Among them, stage 3b were 9%, stage 3c were 11.3% and stage 4 were 79.7% patients. Only 30 patients (34%) could receive IO agents in their treatment regimen across various lines of therapy. In stage 4 NSCLC,35.7% patients were treated with IO agents either in the 1st line or later lines. In stage 3, 5 of 18 patients went on to receive IO agent post definitive chemo radiation. The most common reason for non usage of IO agents were financial constraints (68.9%) including exhaustion of insurance limit, denial by insurance company (20.6%) and non availability of drug (10.5%). Of 30 patients who received IO agents, 8 patients had to withdraw owing to financial toxicity while they were still responding with average time to withdrawal being 7.2 months. Conclusions: This observational study depicts the real world scenario of the difficulties in bringing approved regimen into practice with financial toxicity being the reason the non usage in nearly 60% patients. In low income countries, this needs to be addressed if more number of patients are to be benefitted from IO agents in NSCLC. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest." @default.
• W3142122489 created "2021-04-13" @default.
• W3142122489 creator A5002747589 @default.
• W3142122489 creator A5028195599 @default.
• W3142122489 creator A5031571414 @default.
• W3142122489 creator A5067087415 @default.
• W3142122489 creator A5086911098 @default.
• W3142122489 date "2021-04-01" @default.
• W3142122489 modified "2023-09-26" @default.
• W3142122489 title "128P A real-world scenario of applicability of immuno oncology agents into practice in NSCLC in a resource constrained setting" @default.
• W3142122489 doi "https://doi.org/10.1016/s1556-0864(21)01970-5" @default.
• W3142122489 hasPublicationYear "2021" @default.
• W3142122489 type Work @default.
• W3142122489 sameAs 3142122489 @default.
• W3142122489 citedByCount "0" @default.
• W3142122489 crossrefType "journal-article" @default.
• W3142122489 hasAuthorship W3142122489A5002747589 @default.
• W3142122489 hasAuthorship W3142122489A5028195599 @default.
• W3142122489 hasAuthorship W3142122489A5031571414 @default.
• W3142122489 hasAuthorship W3142122489A5067087415 @default.
• W3142122489 hasAuthorship W3142122489A5086911098 @default.
• W3142122489 hasBestOaLocation W31421224891 @default.
• W3142122489 hasConcept C126322002 @default.
• W3142122489 hasConcept C143998085 @default.
• W3142122489 hasConcept C146357865 @default.
• W3142122489 hasConcept C151730666 @default.
• W3142122489 hasConcept C23131810 @default.
• W3142122489 hasConcept C2776256026 @default.
• W3142122489 hasConcept C2781413609 @default.
• W3142122489 hasConcept C71924100 @default.
• W3142122489 hasConcept C86803240 @default.
• W3142122489 hasConceptScore W3142122489C126322002 @default.
• W3142122489 hasConceptScore W3142122489C143998085 @default.
• W3142122489 hasConceptScore W3142122489C146357865 @default.
• W3142122489 hasConceptScore W3142122489C151730666 @default.
• W3142122489 hasConceptScore W3142122489C23131810 @default.
• W3142122489 hasConceptScore W3142122489C2776256026 @default.
• W3142122489 hasConceptScore W3142122489C2781413609 @default.
• W3142122489 hasConceptScore W3142122489C71924100 @default.
• W3142122489 hasConceptScore W3142122489C86803240 @default.
• W3142122489 hasIssue "4" @default.
• W3142122489 hasLocation W31421224891 @default.
• W3142122489 hasOpenAccess W3142122489 @default.
• W3142122489 hasPrimaryLocation W31421224891 @default.
• W3142122489 hasRelatedWork W2032912323 @default.
• W3142122489 hasRelatedWork W2089045987 @default.
• W3142122489 hasRelatedWork W2313076522 @default.
• W3142122489 hasRelatedWork W2356105190 @default.
• W3142122489 hasRelatedWork W2372561159 @default.
• W3142122489 hasRelatedWork W2390152934 @default.
• W3142122489 hasRelatedWork W2442673159 @default.
• W3142122489 hasRelatedWork W2535269429 @default.
• W3142122489 hasRelatedWork W3011176692 @default.
• W3142122489 hasRelatedWork W2464797648 @default.
• W3142122489 hasVolume "16" @default.
• W3142122489 isParatext "false" @default.
• W3142122489 isRetracted "false" @default.
• W3142122489 magId "3142122489" @default.
• W3142122489 workType "article" @default.